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Edited by Hans EklundAbstract Two classes of quinazolinone derivatives and quinox-
aline derivatives were identiﬁed as potent and selective poly-
(ADP-ribose) polymerase-1 and 2 (PARP-1) and (PARP-2)
inhibitors, respectively. In PARP enzyme assays using recombi-
nant PARP-1 and PARP-2, quinazolinone derivatives displayed
relatively high selectivity for PARP-1 and quinoxaline deriva-
tives showed superior selectivity for PARP-2. SBDD analysis
via a combination of X-ray structural study and homology mod-
eling suggested distinct interactions of inhibitors with PARP-1
and PARP-2. These ﬁndings provide a new structural framework
for the design of selective inhibitors for PARP-1 and PARP-2.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Poly(ADP-ribose) polymerase (PARP) is an abundant nu-
clear enzyme in eukaryotic cells that has been implicated to be-
come activated in response to DNA damage. Activated PARP
catalyzes the transfer of ADP-ribose units from nicotinamide
adenine dinucleotide (NAD+) to nuclear acceptor proteins
such as histones, topoisomerases, DNA polymerases, DNA li-
gases and PARP itself. Excessive activation of PARP con-
sumes NAD+ and consequently ATP, culminating in cell
dysfunction or necrosis. Furthermore, PARP has also been
implicated in a caspase-independent apoptosis pathway medi-
ated by apoptosis-inducing factor [1]. PARP inhibitors pro-
vided remarkable protection from tissue damage in various
forms of reperfusion injury, inﬂammation and neurotoxicityAbbreviations: PARP-1, Poly(ADP-ribose) polymerase-1; PARP-2,
Poly(ADP-ribose) polymerase-2 (PARP-2); NAD+, nicotinamide
adenine dinucleotide; PAR, Poly(ADP-ribose); NI site, nicotinamide-
ribose binding site; AD site, adenine-ribose binding site
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doi:10.1016/j.febslet.2005.01.036in animal models [2]. Thus, inhibition of PARP by pharmaco-
logical agents could be useful in the treatment of inﬂammatory
disease, neurodegenerative disease and several other diseases
involved in PARP activation.
Characterized family members of PARP currently include
the proteins PARP-1, PARP-2, PARP-3, Tankyrase-1, Tank-
yrase-2, TiPARP and vPARP. Although PARP-1 has been
believed to be responsible for all the DNA-damage depen-
dent poly(ADP-ribose) (PAR) synthesis in mammalian cells,
a novel DNA-damage dependent PARP-2 was subsequently
discovered as a result of the presence of residual DNA-
dependent PARP activity in embryonic ﬁbroblasts derived
from PARP-1-deﬁcient mice [3,4]. PARP-1 and PARP-2
are structurally diﬀerent from each other, but they share a
DNA-binding domain and the catalytic domain of PARP-2
has high resemblance to that of PARP-1. The ﬁrst crystal
structure available was that of the catalytic domain of chick-
en PARP-1, which informed of the binding mode of inhibi-
tors to the NAD+ binding site [5]. Recently, the second
crystal structure of murine PARP-2 has been solved. The
catalytic domain of murine PARP-2 is found to be very sim-
ilar to that of PARP-1 [6]. Furthermore, it has been re-
ported that the PARP catalytic domain shows the highest
degree of homology between diﬀerent species [7,8], suggest-
ing that PARP inhibitors may have no species-diﬀerence in
terms of inhibitory activity among human, rat and mouse
PARPs [9].
Over the last two decades, a large number of PARP-1 inhib-
itors have been developed [10], the majority of which mimic to
some degree the nicotinamide moiety of NAD+ and bind to the
donor site of the protein. However, the residues in the donor
site of PARP-1 that provide hydrogen-bonding interactions
with these inhibitors are completely conserved in PARP-2, sug-
gesting that these existing PARP-1 inhibitors would not dis-
criminate between PARP-1 and PARP-2 [6]. We have
recently discovered two classes of quinazolinone structure
and quinoxaline structure as potent and brain penetrable
PARP-1 inhibitors which can represent an attractive therapeu-
tic candidate for neurodegenerative disorders such as cerebral
ischemia or Parkinsons disease [11]. In this paper, we describe
our extensive research on PARP-1/2 selective inhibitors which
discriminate between PARP-1 and PARP-2 using SBDD
analysis by a combination of X-ray analysis and homology
modeling.blished by Elsevier B.V. All rights reserved.
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2.1. Materials
Recombinant human PARP enzyme was purchased from Trevigen,
Inc. (Gaithersburg, MD) and recombinant mouse PARP-1 and
PARP-2 enzymes were purchased from Alexis Biochemicals (San Die-
go, CA). Unless otherwise stated, all other chemicals were purchased
from Sigma–Aldrich (St. Louis, MO).
2.2. PARP assay
To assess the inhibitory activity of novel inhibitors, the PARP en-
zyme assay was carried out in a ﬁnal volume of 100 ll consisting of
50 mM Tris–HCl (pH 8.0), 25 mM MgCl2, 1 mM dithiothreitol,
10 lg activated salmon testes DNA, 0.1 lCi of [adenylate-32P]-NAD,
0.2 units of recombinant human PARP-1, recombinant mouse
PARP-1 or PARP-2, and various concentrations of PARP inhibitors.
The reaction mixture was incubated at room temperature (23 C) for
15 min, and the reaction was terminated by adding 200 ll of ice cold
20% trichloroacetic acid (TCA) and incubated at 4 C for 10 min.
The precipitate was transferred onto GF/B ﬁlter (Packard Uniﬁlter-
GF/B) and washed three times with 10% TCA solution and 70%
ethanol. After the ﬁlter was dried, the radioactivity was determined
by liquid scintillation counting. IC50 values were calculated from the
concentration dependence of the inhibition curves by using com-
puter-assisted non-linear regression analyses.
2.3. X-ray crystallography of 10/PARP-1
The C-terminal catalytic domain of PARP (catPARP) from human
was puriﬁed as described previously [12]. Crystals of catPARP com-
plexed with 10 were obtained by the sitting drop vapor-diﬀusion
method, adding equal volumes of concentrated protein solution
(20 mg/ml) and a crystallization buﬀer (2.2–2.3 M (NH4)2SO4, 1%
v/v PEG400 and 100 mM Tris–HCl, pH 8.0) at 3:1 molar ratio of
10 to protein. The crystal was transferred to cryo-protectant oil, Par-
atone-N (Hampton Research) and ﬂash-cooled in a liquid N2 stream
at 100 K and X-ray diﬀraction data was collected at SPring8/BL32B2,
using a R-Axis V imaging plate detector (Rigaku). The crystal
formed in space group P21 with unit cell parameters, a = 90.05 A˚,
b = 77.08 A˚, c = 113.72 A˚, b = 117.43. The data was processed and
scaled using the program Crystal Clear (Rigaku) at resolution range
of 29.25–3.0 A˚ with overall Rmerge and completeness of 8.5% and
94.0%, respectively, against 26 413 unique reﬂections out of 107 770
observations. Each asymmetric unit contained four protein molecules
with solvent content of 46.0%. The monomer structure of catPARP
(PDB code: 1UK0) [8] was used as the initial model for molecular
replacement with the program AMoRe in the CCP4 package [13].
The resulting model showed four distinct solutions and yielded a cor-
relation coeﬃcient of 59.0% and R-factor of 43.9% through a combi-
nation of the solutions. The tetrameric structure was subsequently
reﬁned with rigid body, simulated annealing, position and restrained
B-factor routine from the program CNX (Accelrys). The ligand could
easily ﬁt into the diﬀerence electron density map and was bound to
all of the four protein molecules in the asymmetric unit with the same
binding mode. After iterative cycles of reﬁnement with position and
restrained B-factor routine from the program CNX (Accelrys), and
manual model improvement with the program QUANTA (Accelrys),
the ﬁnal model yielded conventional and free R-factors of 23.3% and
28.8%, respectively, at a resolution range of 29.25–3.0 A˚. The model
coordinates have been deposited in the Protein Data Bank with the
accession code 1WOK.3. Results and discussion
3.1. SBDD study: quinazolinone structure
PARP-1/2 inhibitory activity of quinazolinone derivatives in
vitro is outlined in Table 1. In general, the inhibitory potency
of these derivatives was found to be largely dependent on the
unique linker of the quinazolinone ring. Quinazolinone linked
with a 4-phenyl-tetrahyropyridine moiety (1) exhibited strong
potency against PARP-1 (IC50: 21 nM), and exhibited anappropriately 30-fold less potency against PARP-2 (IC50:
608 nM). The addition of a chloro group at the 8-position
(2), which is important for bioavailability and brain penetra-
tion, resulted in almost the same activity and selectivity, while
the addition of a chloro group at the 5-position (6) and a
methyl group at the 8-position (5) showed 3 times lower selec-
tivity than 1. On the other hand, well-known inhibitors such as
2-methyl-4(3H)quinazolinone (7) and 3-AB (8) were less selec-
tive, with 0.6 and 0.9, respectively.
Fig. 1 shows the results of a structural study of the catalytic
domain of human PARP-1 and PARP-2 complexes with the
quinazolinone inhibitor 5 by X-ray analysis reﬁned to 3.0 A˚
[8] and homology modeling by FAMS [14] based on the solved
X-ray structure of murine PARP-2 [6]. As expected, there are
no diﬀerences in the nicotinamide-ribose binding site (NI-site)
between PARP-1 and PARP-2. The quinazolinone 5 binds to
the NI site of PARP-2 by three hydrogen bonds (C‚O to
Ser446Oc and Gly405NH; NH to Gly405C‚O) and by a
sandwiched hydrophobic interaction with the phenyl ring of
Tyr438 and Tyr449 (Fig. 1B). We have reported that the design
of the related quinazolinone analogue by modeling to allow a
maximum ﬁx of the 4-phenyl-tetrahydropyridine moiety to the
adenine-ribose binding site (AD-site) of PARP-1. The terminal
phenyl ring lies in a deep hydrophobic pocket which consists of
the side chains of Leu769, Ile879, Pro881, and the methylene
chain of Arg878 in PARP-1 (Fig. 1C). However, the critical
diﬀerence between PARP-1 and PARP-2 in this hydrophobic
pocket is the replacement of Leu769 in PARP-1, with
Gly314 in PARP-2 (Fig. 1D). Based on these ﬁndings, it is
clearly suggested that replacement of Leu769 by Gly314 leads
to loss of a hydrophobic pocket and leads to a loss of potency
against PARP-2. The change of only one amino acid is there-
fore suﬃcient to allow discrimination between PARP-1 and
PARP-2.3.2. SBDD study: quinoxaline structure
The SAR results of quinoxaline derivatives are outlined in
Table 2. The activity of these inhibitors against PARP-2 is
about 10-fold more potent than against PARP-1. Substitution
at the para position of the terminal phenyl ring was more
advantageous to activity than either meta or ortho substitution
(data not shown). A twofold improvement in activity against
PARP-2 was obtained by p-chloro (10) with IC50 = 7.0 nM
and selectivity: 0.21.
To validate our results, we performed structural analysis by
X-ray crystallography of human PARP-1 complexes with qui-
noxaline ligand and molecular modeling of PARP-2. Fig. 2A
shows the structure of the human catalytic domain of
PARP-1 complex with 10, reﬁned to 3.0 A˚. The binding mode
of human PARP-1 with 10 is almost the same as that of the
previously disclosed benzimidazole analogues [15]. The car-
boxamide part of the inhibitor tightly binds to the same NI site
by the three critical hydrogen bonds with Ser904 and Gly863
and the nitrogen of the quinoxaline ring binds to the carbox-
ylic acid of Glu988, suggesting that this binding mode was con-
served in PARP-2 (Fig. 2B). However, the main diﬀerences in
the binding site of the terminal phenyl group of quinoxaline
analogues within the groove could be used to introduce dis-
crimination between PARP-1 and PARP-2. The Cl-phenyl
group of 10 provides secondary contacts to the side chain of
Asp766 formed by hydrogen bond with Tyr889, which replaces
Fig. 1. (A) X-ray structure (3.0 A˚ resolution) of compound 5 in complex with human PARP-1 catalytic domain. 5 is yellow with heteroatoms being
blue for nitrogen, red for oxygen, and green for ﬂuoride. Important residues in the NI site are shown ball and stick style. (B) Homology modeled
structure of compound 5 in complex with human PARP-2 catalytic domain based on the solved X-ray structure (2.8 A˚ resolution) of murine PARP-
2. Important residues in the NI site are shown ball and stick style. (C) Close-up views of the terminal site of 5 in the AD site of PARP-1. (D) Close-up
views of the terminal site of 5 in the AD site of PARP-2.
Table 1
PARP-1/2 inhibitory activities of quinazolinone analogues
N
NH
O
N
R2
R3R1
Compound R1 R2 R3 PARP-1 IC50 (nM)
a PARP-2 IC50 (nM)
a Selectivity PARP-2/1
1 H H H 21 ± 1.9 608 ± 12.9 29
2 H Cl H 23 ± 1.8 610 ± 18.1 27
3 H Cl CN 3.0 ± 0.6 87 ± 3.6 29
4 H Cl F 13 ± 1.3 500 ± 15.2 39
5 H Me F 16 ± 1.1 167 ± 25.7 10
6 Cl H H 68 ± 2.4 630 ± 28.5 9
7b 1200 ± 80 660 ± 24.7 0.6
8c 11200 ± 810 9810 ± 770 0.9
aThe values are presented as means ± S.E. of three independent experiments (each experiment was triplicate).
b5-Chloro-2-methyl-4(3H)-quinazolinone.
c3-Aminobenzamide.
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The second source of selectivity results from the replacement
of Glu763 in PARP-1 with Gln308 in PARP-2. X-ray analysis
shows that the side chain of Glu763 in PARP-1 is restricted by
a hydrogen bond with neighbor Gln759 and Ala760 (Fig. 2A)
[16], while the residue of Gln308 in PARP-2 would be mobilemake a more favorable interaction with the Cl-phenyl group,
since the previous study indicated the side chain of Gln763
in chicken PARP-1 appeared to be mobile and movement of
this residue nicely accommodated the p-benzylamine substitu-
tion of inhibitors [15,17]. It is considered that the Cl-phenyl
group extends into this groove containing Glu311 and
Fig. 2. (A) X-ray structure (3.0 A˚ resolution) of compound 10 in complex with human PARP-1 catalytic domain. 10 is yellow with heteroatoms being
blue for nitrogen, red for oxygen, and green for ﬂuoride. Important residues in the NI site are shown ball and stick style. (B) Homology modeled
structure of compound 10 in complex with human PARP-2 catalytic domain based on the solved X-ray structure (2.8 A˚ resolution) of murine PARP-
2. Important residues in the NI site are shown ball and stick style. (C) Close-up views for the binding mode of the Cl-Phenyl site of 10 in PARP-1. (D)
Close-up views for the binding mode of the Cl-Phenyl site of 10 in PARP-2.
Table 2
PARP-1/2 inhibitory activities of quinoxaline analogues
N
N
O NH2 R
Compound R PARP-1 IC50 (nM)
a PARP-2 IC50 (nM)
a Selectivity PARP-2/1
9 H 131 ± 2.6 14 ± 1.3 0.11
10 Cl 33 ± 0.9 7.0 ± 2.0 0.21
11 CN 101 ± 1.8 8.0 ± 1.0 0.08
12 CF3 118 ± 3.1 11 ± 0.9 0.09
13 OMe 71 ± 2.2 8.0 ± 0.8 0.11
14 NH2 87 ± 3.8 9.0 ± 1.0 0.10
aThe values are presented as means ± S.E. of three independent experiments (each experiment was triplicate).
1392 A. Iwashita et al. / FEBS Letters 579 (2005) 1389–1393Gln308 in PARP-2 to make a more favorable interaction and
may account for the increase in potency observed (Fig. 2C vs.
D).
In summary, we have discovered ﬁrst PARP-1 and PARP-2
selective inhibitors. SBDD study by a combination of X-ray
analysis and homology modeling has revealed the distinct
binding mode for the discrimination between ligands and
PARP-1/2. These ﬁndings provide a new structural concept
for the design of selective inhibitors for PARP-1 and
PARP-2.Acknowledgements:We express our thanks to Dr. David Barrett for his
critical reading of the manuscript.References
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